VNDA Vanda Pharmaceuticals Inc.
Healthcare$6.22+0.48%ClosedMarket Cap: $374.0M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.31
P/S
1.71
EV/EBITDA
-2.31
DCF Value
$-6.88
FCF Yield
-34.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.5%
Operating Margin
-73.6%
Net Margin
-110.0%
ROE
-61.4%
ROA
-55.3%
ROIC
-52.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $51.7M | 90.0% | $-50.2M | $-48.6M | $— | — |
| Q4 null | $57.2M | 93.3% | $-40.4M | $-141.2M | $— | — |
| FY null | $216.1M | 94.0% | $-151.2M | $-220.5M | $— | — |
| Q3 null | $56.3M | 94.7% | $-31.3M | $-22.6M | $— | — |
| Q2 null | $52.6M | 91.5% | $-38.5M | $-27.2M | $— | — |
| Q1 null | $50.0M | 93.0% | $-44.5M | $-29.5M | $— | — |
| Q4 null | $53.2M | 95.1% | $-10.3M | $-4.9M | $— | — |
| FY null | $198.8M | 94.3% | $-40.7M | $-18.9M | $— | — |
| Q3 null | $47.7M | 94.6% | $-11.0M | $-5.3M | $— | — |
| Q2 null | $50.5M | 91.1% | $-10.1M | $-4.5M | $— | — |
| Q1 null | $47.5M | 88.5% | $-9.2M | $-4.1M | $— | — |
| Q4 2023 | $45.3M | 92.4% | $-7.1M | $-2.4M | $-0.04 | — |